Optimisation of antihypertensive treatment by crossover rotation of four major classes
- PMID: 10376615
- DOI: 10.1016/s0140-6736(98)07614-4
Optimisation of antihypertensive treatment by crossover rotation of four major classes
Abstract
Background: Most comparisons of antihypertensive drugs are undertaken in parallel groups. We undertook a crossover rotation of the four main classes of antihypertensive drugs, in untreated young hypertensive patients, to assess the response rate with monotherapy achieved by a systematic rotation.
Methods: 56 patients, mean blood pressure 161/98 mm Hg, entered the rotation, of whom 36 received all four monthly cycles of treatment with an angiotensin-converting-enzyme (ACE) inhibitor (A), beta-blocker (B), calcium-channel blocker (C), and diuretic (D). Each patient's best drug was then repeated to assess repeatability. Two measures of individual variability in response were used. First, the value of rotation was measured by the increased proportion of patients reaching target blood pressure on their best drug versus their first drug. Second, we assessed whether the responses to each drug were correlated with each other.
Findings: Significant variability in response was found. 20 of the 41 patients reaching target blood pressure (< or =140/90 mm Hg) failed to achieve this target on their first drug. Rotation increased from 22/56 (39%) to 41/56 (73%) the success of monotherapy (p=0.0001); in half the patients, blood-pressure on the best treatment was 135/85 mm Hg or less. There were significant correlations between the blood pressure responses to A and B (r=0.5, p<0.01), and C and D (r=0.6, p<0.001), but not between the other four pairings of treatments. The responses to the AB pair were, on average, at least 50% higher than those to the CD pair; this difference was highly significant by multivariate repeated-measures ANOVA.
Interpretation: There is a marked variability in hypertensive patients' response to different antihypertensive drugs. The basis may be underlying variability in types of essential hypertension. Optimisation of treatment requires systematic rotation through several therapies; however, an "AB/CD" rule is proposed in which one of each of the two pairs of treatments is initially selected to abbreviate the rotation in routine practice.
Comment in
-
Antihypertensive treatment.Lancet. 1999 Sep 18;354(9183):1028; author reply 1028-9. doi: 10.1016/S0140-6736(99)00167-1. Lancet. 1999. PMID: 10501384 No abstract available.
-
Antihypertensive treatment.Lancet. 1999 Sep 18;354(9183):1028; author reply 1028-9. doi: 10.1016/S0140-6736(05)76630-7. Lancet. 1999. PMID: 10501385 No abstract available.
Similar articles
-
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.J Hypertens. 2002 Apr;20(4):771-7. doi: 10.1097/00004872-200204000-00037. J Hypertens. 2002. PMID: 11910315 Clinical Trial.
-
ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension.Am J Hypertens. 2001 Mar;14(3):241-7. doi: 10.1016/s0895-7061(00)01266-8. Am J Hypertens. 2001. PMID: 11281235 Clinical Trial.
-
Association between cardiovascular outcomes and antihypertensive drug treatment in older women.JAMA. 2004 Dec 15;292(23):2849-59. doi: 10.1001/jama.292.23.2849. JAMA. 2004. PMID: 15598916
-
The need for evidence in hypertension management: historical perspective.Ann Saudi Med. 2005 Sep-Oct;25(5):367-74. Ann Saudi Med. 2005. PMID: 16270757 Review.
-
The role of combination therapy in the treatment of hypertension.Am J Hypertens. 1998 Jun;11(6 Pt 2):73S-78S; discussion 95S-100S. doi: 10.1016/s0895-7061(98)00060-0. Am J Hypertens. 1998. PMID: 9655566 Review.
Cited by
-
Decision support and safety of clinical environments.Qual Saf Health Care. 2002 Mar;11(1):69-75. doi: 10.1136/qhc.11.1.69. Qual Saf Health Care. 2002. PMID: 12078374 Free PMC article.
-
Drug treatment of hypertension: implications of ALLHAT.Heart. 2003 Jun;89(6):589-90. doi: 10.1136/heart.89.6.589. Heart. 2003. PMID: 12748205 Free PMC article. No abstract available.
-
Renin: friend or foe?Heart. 2007 Sep;93(9):1026-33. doi: 10.1136/hrt.2006.107706. Epub 2007 May 8. Heart. 2007. PMID: 17488768 Free PMC article. Review.
-
Predicting changes in hypertension control using electronic health records from a chronic disease management program.J Am Med Inform Assoc. 2014 Mar-Apr;21(2):337-44. doi: 10.1136/amiajnl-2013-002033. Epub 2013 Sep 17. J Am Med Inform Assoc. 2014. PMID: 24045907 Free PMC article.
-
Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial.J Hum Hypertens. 2015 Jan;29(1):22-7. doi: 10.1038/jhh.2014.29. Epub 2014 Apr 17. J Hum Hypertens. 2015. PMID: 24739801 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous